FLT1 and pancreatic neoplasm: To overcome this therapeutic failure, a triple angiokinase inhibitor targeting VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β signalling—nintedanib—was explored in the preclinical models of pancreatic cancer [76].